Literature DB >> 35120629

Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity.

Stéphanie S Cornelis1, Esmee H Runhart2, Miriam Bauwens3, Zelia Corradi1, Elfride De Baere3, Susanne Roosing1, Lonneke Haer-Wigman1, Claire-Marie Dhaenens4, Anneke T Vulto-van Silfhout1, Frans P M Cremers5.   

Abstract

Recurrence risk calculations in autosomal recessive diseases are complicated when the effect of genetic variants and their population frequencies and penetrances are unknown. An example of this is Stargardt disease (STGD1), a frequent recessive retinal disease caused by bi-allelic pathogenic variants in ABCA4. In this cross-sectional study, 1,619 ABCA4 variants from 5,579 individuals with STGD1 were collected and categorized by (1) severity based on statistical comparisons of their frequencies in STGD1-affected individuals versus the general population, (2) their observed versus expected homozygous occurrence in STGD1-affected individuals, (3) their occurrence in combination with established mild alleles in STGD1-affected individuals, and (4) previous functional and clinical studies. We used the sum allele frequencies of these severity categories to estimate recurrence risks for offspring of STGD1-affected individuals and carriers of pathogenic ABCA4 variants. The risk for offspring of an STGD1-affected individual with the "severe|severe" genotype or a "severe|mild with complete penetrance" genotype to develop STGD1 at some moment in life was estimated at 2.8%-3.1% (1 in 36-32 individuals) and 1.6%-1.8% (1 in 62-57 individuals), respectively. The risk to develop STGD1 in childhood was estimated to be 2- to 4-fold lower: 0.68%-0.79% (1 in 148-126) and 0.34%-0.39% (1 in 296-252), respectively. In conclusion, we established personalized recurrence risk calculations for STGD1-affected individuals with different combinations of variants. We thus propose an expanded genotype-based personalized counseling to appreciate the variable recurrence risks for STGD1-affected individuals. This represents a conceptual breakthrough because risk calculations for STGD1 may be exemplary for many other inherited diseases.
Copyright © 2022 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  STGD1, recurrence risk, ABCA4, genotype-phenotype correlation, personalized genetic counseling, autosomal recessive disease

Mesh:

Substances:

Year:  2022        PMID: 35120629      PMCID: PMC8948157          DOI: 10.1016/j.ajhg.2022.01.008

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.043


  44 in total

1.  Frequent hypomorphic alleles account for a significant fraction of ABCA4 disease and distinguish it from age-related macular degeneration.

Authors:  Jana Zernant; Winston Lee; Frederick T Collison; Gerald A Fishman; Yuri V Sergeev; Kaspar Schuerch; Janet R Sparrow; Stephen H Tsang; Rando Allikmets
Journal:  J Med Genet       Date:  2017-04-26       Impact factor: 6.318

2.  Clinical and genetic characteristics of late-onset Stargardt's disease.

Authors:  Sarah C Westeneng-van Haaften; Camiel J F Boon; Frans P M Cremers; Lies H Hoefsloot; Anneke I den Hollander; Carel B Hoyng
Journal:  Ophthalmology       Date:  2012-03-24       Impact factor: 12.079

3.  Two CFTR mutations within codon 970 differently impact on the chloride channel functionality.

Authors:  Felice Amato; Paolo Scudieri; Ilaria Musante; Valeria Tomati; Emanuela Caci; Marika Comegna; Sabrina Maietta; Francesca Manzoni; Antonella Miriam Di Lullo; Elke De Wachter; Eef Vanderhelst; Vito Terlizzi; Cesare Braggion; Giuseppe Castaldo; Luis J V Galietta
Journal:  Hum Mutat       Date:  2019-03-28       Impact factor: 4.878

4.  Comparative ex vivo, in vitro and in silico analyses of a CFTR splicing mutation: Importance of functional studies to establish disease liability of mutations.

Authors:  Anabela S Ramalho; Luka A Clarke; Marisa Sousa; Verónica Felicio; Celeste Barreto; Carlos Lopes; Margarida D Amaral
Journal:  J Cyst Fibros       Date:  2015-02-27       Impact factor: 5.482

5.  Diagnostic exome-based preconception carrier testing in consanguineous couples: results from the first 100 couples in clinical practice.

Authors:  Suzanne C E H Sallevelt; Alexander P A Stegmann; Bart de Koning; Crool Velter; Anja Steyls; Melanie van Esch; Phillis Lakeman; Helger Yntema; Masoud Zamani Esteki; Christine E M de Die-Smulders; Christian Gilissen; Arthur van den Wijngaard; Han G Brunner; Aimée D C Paulussen
Journal:  Genet Med       Date:  2021-03-19       Impact factor: 8.822

6.  Extremely hypomorphic and severe deep intronic variants in the ABCA4 locus result in varying Stargardt disease phenotypes.

Authors:  Jana Zernant; Winston Lee; Takayuki Nagasaki; Frederick T Collison; Gerald A Fishman; Mette Bertelsen; Thomas Rosenberg; Peter Gouras; Stephen H Tsang; Rando Allikmets
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-08-01

Review 7.  Frequency of ABCA4 mutations in 278 Spanish controls: an insight into the prevalence of autosomal recessive Stargardt disease.

Authors:  R Riveiro-Alvarez; J Aguirre-Lamban; M Angel Lopez-Martinez; M Jose Trujillo-Tiebas; D Cantalapiedra; E Vallespin; A Avila-Fernandez; C Ramos; C Ayuso
Journal:  Br J Ophthalmol       Date:  2008-10-31       Impact factor: 4.638

8.  ABCA4-Associated Stargardt Disease.

Authors:  Mubeen Khan; Frans P M Cremers
Journal:  Klin Monbl Augenheilkd       Date:  2020-02-03       Impact factor: 0.700

Review 9.  Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2.

Authors:  M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan
Journal:  Hum Genet       Date:  2021-07-30       Impact factor: 4.132

10.  Non-exomic and synonymous variants in ABCA4 are an important cause of Stargardt disease.

Authors:  Terry A Braun; Robert F Mullins; Alex H Wagner; Jeaneen L Andorf; Rebecca M Johnston; Benjamin B Bakall; Adam P Deluca; Gerald A Fishman; Byron L Lam; Richard G Weleber; Artur V Cideciyan; Samuel G Jacobson; Val C Sheffield; Budd A Tucker; Edwin M Stone
Journal:  Hum Mol Genet       Date:  2013-08-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.